227 related articles for article (PubMed ID: 21514317)
21. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
22. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
[TBL] [Abstract][Full Text] [Related]
24. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
25. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
Mattammal MB; Haring JH; Chung HD; Raghu G; Strong R
Neurodegeneration; 1995 Sep; 4(3):271-81. PubMed ID: 8581559
[TBL] [Abstract][Full Text] [Related]
26. [Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)].
Bonnet JJ; Legros H; Janin F; Dourmap N; Costentin J
Ann Pharm Fr; 2004 Sep; 62(5):323-31. PubMed ID: 15314580
[TBL] [Abstract][Full Text] [Related]
27. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones.
Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J
J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456
[TBL] [Abstract][Full Text] [Related]
28. Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.
Anderson DG; Florang VR; Schamp JH; Buettner GR; Doorn JA
Chem Res Toxicol; 2016 Jul; 29(7):1098-107. PubMed ID: 27268734
[TBL] [Abstract][Full Text] [Related]
29. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
30. Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.
Ito S; Tanaka H; Ojika M; Wakamatsu K; Sugumaran M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769179
[TBL] [Abstract][Full Text] [Related]
31. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
Werner-Allen JW; DuMond JF; Levine RL; Bax A
Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
[TBL] [Abstract][Full Text] [Related]
32. Catechols in post-mortem brain of patients with Parkinson disease.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
[TBL] [Abstract][Full Text] [Related]
33. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
34. PCB95 and PCB153 change dopamine levels and turn-over in PC12 cells.
Enayah SH; Vanle BC; Fuortes LJ; Doorn JA; Ludewig G
Toxicology; 2018 Feb; 394():93-101. PubMed ID: 29233657
[TBL] [Abstract][Full Text] [Related]
35. Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo.
Vecchio LM; Sullivan P; Dunn AR; Bermejo MK; Fu R; Masoud ST; Gregersen E; Urs NM; Nazari R; Jensen PH; Ramsey A; Goldstein DS; Miller GW; Salahpour A
J Neurochem; 2021 Aug; 158(4):960-979. PubMed ID: 33991113
[TBL] [Abstract][Full Text] [Related]
36. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
37. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
38. The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
Goldstein DS
Semin Neurol; 2020 Oct; 40(5):502-514. PubMed ID: 32906170
[TBL] [Abstract][Full Text] [Related]
39. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
[TBL] [Abstract][Full Text] [Related]
40. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
